A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Na ïve Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma (MCL) Interventions: Drug: Acalabrutinib; Drug: Venetoclax; Drug: Rituximab Sponsor: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 19, 2023 Category: Research Source Type: clinical trials
Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
Condition: Diffuse Large B-Cell Lymphoma Interventions: Drug: Acalabrutinib; Biological: Rituximab Sponsor: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 19, 2023 Category: Research Source Type: clinical trials
A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Na ïve Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma (MCL) Interventions: Drug: Acalabrutinib; Drug: Venetoclax; Drug: Rituximab Sponsor: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 19, 2023 Category: Research Source Type: clinical trials
Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
Condition: Diffuse Large B-Cell Lymphoma Interventions: Drug: Acalabrutinib; Biological: Rituximab Sponsor: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 19, 2023 Category: Research Source Type: clinical trials
A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Na ïve Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma (MCL) Interventions: Drug: Acalabrutinib; Drug: Venetoclax; Drug: Rituximab Sponsor: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 19, 2023 Category: Research Source Type: clinical trials
Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
Condition: Diffuse Large B-Cell Lymphoma Interventions: Drug: Acalabrutinib; Biological: Rituximab Sponsor: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 19, 2023 Category: Research Source Type: clinical trials
A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Na ïve Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma (MCL) Interventions: Drug: Acalabrutinib; Drug: Venetoclax; Drug: Rituximab Sponsor: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 19, 2023 Category: Research Source Type: clinical trials
Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
Condition: Diffuse Large B-Cell Lymphoma Interventions: Drug: Acalabrutinib; Biological: Rituximab Sponsor: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 19, 2023 Category: Research Source Type: clinical trials
A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Na ïve Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma (MCL) Interventions: Drug: Acalabrutinib; Drug: Venetoclax; Drug: Rituximab Sponsor: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 19, 2023 Category: Research Source Type: clinical trials
Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
Condition: Diffuse Large B-Cell Lymphoma Interventions: Drug: Acalabrutinib; Biological: Rituximab Sponsor: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 19, 2023 Category: Research Source Type: clinical trials
A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Na ïve Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma (MCL) Interventions: Drug: Acalabrutinib; Drug: Venetoclax; Drug: Rituximab Sponsor: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 19, 2023 Category: Research Source Type: clinical trials
Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
Condition: Diffuse Large B-Cell Lymphoma Interventions: Drug: Acalabrutinib; Biological: Rituximab Sponsor: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 19, 2023 Category: Research Source Type: clinical trials
A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Na ïve Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma (MCL) Interventions: Drug: Acalabrutinib; Drug: Venetoclax; Drug: Rituximab Sponsor: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 19, 2023 Category: Research Source Type: clinical trials
Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
Condition: Diffuse Large B-Cell Lymphoma Interventions: Drug: Acalabrutinib; Biological: Rituximab Sponsor: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 19, 2023 Category: Research Source Type: clinical trials
A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Na ïve Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma (MCL) Interventions: Drug: Acalabrutinib; Drug: Venetoclax; Drug: Rituximab Sponsor: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 19, 2023 Category: Research Source Type: clinical trials